Dual MAPK / PI3K pathway inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS mutant and wild type melanoma
Algazi, Alain P., Esteve-Puig, Rosaura, Nosrati, Adi, Hinds, Brian, Hobbs-Muthukumar, Adele, Nandoskar, Prachi, Ortiz-Urda, Susana, Chapman, Paul B., Daud, AdilLanguage:
english
Journal:
Pigment Cell & Melanoma Research
DOI:
10.1111/pcmr.12644
Date:
September, 2017
File:
PDF, 516 KB
english, 2017